<DOC>
	<DOC>NCT01043458</DOC>
	<brief_summary>A study to investigate the process by which ABT-126 is absorbed, distributed, metabolized and eliminated by the body of stable schizophrenic volunteers receiving treatment with an atypical antipsychotic.</brief_summary>
	<brief_title>Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Subject has signed informed consent; Current diagnosis of schizophrenia; Clinically stable on the same single secondgeneration (atypical) antipsychotic for the past 8 weeks; Meets studyspecific criteria for Positive and Negative Syndrome Scale (PANSS); Females are not pregnant, not breastfeeding; Females are postmenopausal or surgically sterile or practicing birth control; Males are surgically sterile or agree to be sexually inactive or use barrier method of birth control Diagnosis of schizoaffective disorder; Diagnosis with mental retardation; Subject has a substance dependence disorder that has not been in sustained remission for at least 1 year; Acute psychosis hospitalization within past 6 months; Bipolar disorder, manic episode, dementia, obsessivecompulsive disorder, or druginduced psychosis or current major depressive disorder; Current clozapine treatment; Suicidal ideation or behavior; BMI of 39 or greater; Relevant drug sensitivity or allergy; Positive hepatitis or HIV test result; positive urine screen for drugs of abuse or alcohol; Recent clinically significant illness/infection or surgery; Recent blood product transfusion, donation or loss of 5 mL/kg of blood;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Pharmacokinetics</keyword>
</DOC>